Students must also take two advanced elective courses selected from those offered by this or other departments. Students are able to select a course of studies uniquely suited to their own career goals.
During their first year of study, students will complete ~8-week research rotations in addition to their coursework. They will initiate dissertation research by the end of their first year and complete elective courses relevant to their developing interests in subsequent years of training.
During the second year of study, students will be required to pass a qualifying examination conducted as prescribed by the Doctor of Philosophy Board of the University. This examination will probe the depth and breadth of the student’s knowledge of the biomedical subjects taught in the core courses.
The candidate is required to present a written dissertation based on original research undertaken while in residence as a graduate student and to present a departmental seminar describing the thesis research.
Students seeking admission to or who are already participating in the M.D. program in the School of Medicine may participate in a program leading to both the M.D. and the Ph.D. degrees.
Toth, M. The Other Side of the Coin, Hypersociability. Genes, Brain, and Behavior 2019
Related links.
A strength of the Pharmacology Program at Cornell is that the research of many of the faculty is focused on therapies for a variety of diseases, and several faculty have clinical responsibilities or close association with clinical faculty at Weill Cornell Medical College and/or Memorial Sloan-Kettering Cancer Institute. This allows students and fellows in the Pharmacology Program to perform research which will result in better or new therapies for diseases such as cancer, epilepsy, Alzheimer's disease, diabetes, mental illness and heart disease.
The goal of the Pharmacology Program is to produce scientists who possess knowledge of pharmacology, as well as a foundation of understanding of biochemistry, molecular biology, chemical biology, and cell and organ physiology. Students and postdoctoral fellows also have ample opportunities to improve their scientific communication skills, both by writing research papers and by presenting their research data at laboratory meetings, at the Pharmacology Program Retreat, and at national scientific meetings. Ph.D. students and postdoctoral fellows have the option of teaching, but this in not a required part of the program. We want our students and fellows to be prepared for productive research careers in academia, government and industry. Lectures about various career paths are presented regularly to assist students and fellows in planning for their futures. Finally, the program provides students and fellows with a group of supportive, helpful and spirited colleagues who enjoy their work and each other. The Weill Cornell Pharmacology Graduate Program was rated 4th in the USA in New York City by the prestigious National Research Council. The National Research Council (NRC) of the USA is the working arm of the National Academies of the United States. To find out more about the Weill Cornell Pharmacology PhD Program, view our rating . This rating was done in 2010 by the National Research Council, part of the USA National Academy of Sciences, #4 Cornell University is the Weill Cornell Pharmacology Graduate Program (located in New York City) of Cornell University. (Weill Cornell Medical College is rated 9th in the USA among medical schools (2019 rating)
Weill Cornell Medicine Pharmacology 1300 York Avenue, Room E-409 New York, NY 10021 Phone: (212) 746-6250 Fax: (212) 746-8835
Cu anschutz medical campus.
Pharmaceutical Outcomes Research is a PhD program in the graduate program in Clinical Pharmacy. This program is housed in the Center for Pharmaceutical Outcomes Research (CePOR, SEE-por), a school-wide center in the Skaggs School of Pharmacy. Our doctoral curriculum is designed to provide competent and highly skilled researchers in the study of patient, provider, or population-level health care and health system interventions. We most often focus on economic, clinical, and humanistic outcomes such as clinical or cost effectiveness or safety. Areas of focus available to students undertaking this course of study include pharmacoeconomics, pharmacoepidemiology, health services research, and drug policy.
Core faculty are methodological experts and provide collaborative linkage to clinical experts in all pharmacy, medicine, nursing, and public health. Programs of study are tailored to student interests in disease or drug areas, such as cardiology, psychiatry, neurology, and cancer. Opportunities exist to link to more basic science colleagues depending on your topic of interests. For example, students interested in drug safety might link with toxicology faculty, or in gene-environment interactions might link with pharmacogenomics faculty.
Applications for all doctoral programs are submitted electronically through the Graduate School of the University of Colorado Denver. After signing up for an account, select 'PhD' under the 'Academic Interests' menu and scroll down to 'Skaggs School of Pharmacy and Pharmaceutical Sciences' and select "PhD in Pharmaceutical Outcomes Research."
Application requirements are:
Additionally:
Application opens September 1, 2023. Applications will not be reviewed until all required materials have been received. The application deadline for Fall 2024 admission is December 1, 2023 for all students.
Admission to the program may include financial support via a stipend awarded on a 12-month basis.
Although a priority of the School of Pharmacy is to provide financial support to its graduate students, payment of stipend, tuition and any fees by the School of Pharmacy or by grants, contracts or gifts to the School of Pharmacy faculty is contingent upon availability of funding, satisfactory academic progress (as defined by the UCD Graduate School, Graduate Student Handbook) and completion of required teaching duties, core courses, and examinations. The School of Pharmacy also reserves the right to review and adjust its funding policies at any time. All students are expected to work full-time toward program requirements for 12 months of the year.
Generally, the first year of financial support will be in the form of stipend support for working as a teaching assistant. Depending on availability, teaching assistantships may be offered beyond one year to students. Faculty may choose to offer research assistant scholarships to students as well. Other funding opportunities in the form of external student grants and awards also exist. Students are encouraged to talk to the faculty about funding and scholarship opportunities. Funds for travel to one meeting where students are presenting a poster or giving a podium presentation are limited to $500 per fiscal year.
Students who do not remain in good graduate standing (3.0 GPA or above) or maintain satisfactory academic progress are placed on academic probation. Probation and suspension policies are described in the UCD Graduate School, Graduate Student Handbook. Payment of stipend, tuition, insurance and fees for a student while on academic probation is at the discretion of the graduate program committee.
What kind of students should pursue a phd degree in pharmaceutical outcomes research why should you apply to this program.
We are looking for students who want to influence healthcare but do not want to be a provider. With the belief that the research done will allow for the application of new knowledge towards health improvement.
The benefits of this program are multi-faceted. Housed on a major medical campus, students will be able to collaborate with the schools of pharmacy, medicine, nursing, and public health. Also the University of Colorado Hospital, Children's Hospital, and the Veterans Affairs Medical Center are located on campus.
By having a small group of graduate students, they are allowed more time with the faculty members. With two faculty members from each component, students will be able to have the support necessary to complete their degree.
Graduates of the program will have many career options within these areas:
There is a critical need for individuals who are able to conduct rigorous, credible, and relevant population and patient-based research within stringent ethical and regulatory guidelines; the demand for such researchers is expected to grow given the developing health care reform and the investment in federal development and expansion on comparative effectiveness research.
Past graduates have gone on to be an interim dean at a Regis University and the director of pharmacy at the University of Colorado Hospital
Our students often win awards at regional and national symposium (such as Julia Slejko at ISPOR or SMDM). One holds a prestigious pre-doctoral dissertation award in health outcomes from the PhRMA Foundation. Two have completed comprehensive exams are working on defending their dissertation proposals. All these more advanced students have published manuscripts in peer-reviewed journals as first authors with the mentorship of the CePOR faculty.
Heather Anderson, PhD What's great about this campus is that we are able to collaborate with other schools such as public health, nursing, and medicine. While many Pharmaceutical Outcomes Research programs have a major focus on economics, we do that and more. Our program has a strong focus on epidemiology and policy too. I actually got my PhD in epidemiology from our School of Public health and can link up students with the best courses and advise on exciting local opportunities for research assistantships.
Kelly Anderson, PhD Training at a world-class medical campus allows PhD students in the Center for Pharmaceutical Outcomes Research to engage with faculty in the center with expertise in outcomes research, drug pricing, economics, epidemiology, and health policy, and also have the opportunity to learn from and collaborate with faculty throughout the Schools of Pharmacy, Public Health, Medicine, Dentistry, and Nursing. For anyone who loves big data, our faculty also work with numerous large data sets: Medicare claims, linked EHR-claims data, and all-payer data just to name a few. As a lot of my work is focused on payment policy, I welcome the opportunity to engage students as they think about the real-world implications of their research for policy makers, health insurers, patients, clinicians, and drug companies and disseminate their findings to these key stakeholders.
R. Brett McQueen, PhD Pharmaceutical outcomes research includes aspects of multiple disciplines including math, economics, and epidemiology. I joined the faculty at CU to contribute to comparative- and cost-effectiveness research and to education both for the PhD and the PharmD programs. Our PhD program emphasizes quality over quantity. We maintain a very favorable student to faculty ratio, we offer competitive student financial support, and we strive to graduate scientific leaders in the field of outcomes research.
Kavita V. Nair, PhD Our expectations for graduate students are high and we have structured the education and training requirements to help you meet these goals. I will require a lot of you as a student but will also be your strongest advocate!
Robert Valuck, PhD, RPh I believe that the strengths of our program are the skills and the diversity of the faculty, and size and connectedness of our program with others on campus and in the state and region. With a smaller number of graduate students in our program, they are able to spend more time with faculty members. Our program is well connected with others on the Anschutz campus, and students have opportunities to collaborate both across campus, and with state agencies, provider groups, and others that have an interest in outcomes research and its applications to patient care and policy.
Advance the science of pharmaceutical outcomes research by training scientists who generate and synthesize evidence to inform practice and policy.
The goal of the PhD n pharmaceutical outcomes research is to develop methodological experts. Graduates will have the knowledge and extensive skills necessary to conduct pharmacoeconomic, pharmacoepidemiologic, health services, and drug policy research. We train individuals who can contribute to T3-T4 clinical translational pharmacy and pharmaceutical sciences, specifically on effective, population health, and policy studies. These contributions should ultimately benefit pharmacists and society with safe, effective, and efficient use of pharmaceutical care.
The Pharmaceutical Outcomes Research PhD program trains graduate students to become proficient and successful investigators who are able to:
Required Courses | |
BIOS 6611 & 6612 | Biostatistical Methods I and Biostatistical Methods II |
EPID 6630 | Epidemiology |
EPID 6626 | Research Methods in Epidemiology |
HSMP 6601 | Introduction to Health Systems Management and Policy |
HSMP 6609 | Cost Benefit and Effectiveness in Health |
HSMP 7609 or | Methods in Health Services Research II or |
EPID 6631 | Analytical Epidemiology |
PHOR 7611 | Applied Cost-Effectiveness Modeling (McQueen) |
PHOR 7613 | Pharmaceutical Economics (K. Anderson) |
PHOR 7615 | Pharmacoepidemiology (Valuck/H. Anderson) |
CLSC 7150 | Ethics and Regulation in Human Subjects Review |
PHOR 7570 | Graduate Student Seminar (1 credit per semester; PHOR faculty) |
PHOR 8990 | Doctoral Dissertation |
Approved Elective Courses | |
BIOS 6643 | Analysis of Longitudinal Data |
BIOS 6646 | Survival Analysis |
BIOS 6648/6649 | Design of Clinical Trials and Experiments (can take 6648 OR 6649) |
BIOS 6649 | Design of Studies in the Health Sciences |
BIOS 6659 | Statistical Methods in Genomics |
BIOS 6680 | SAS Programming for Data Analysis |
BIOS 6683 | Introduction to Health Information Technology |
BIOS 7711-7713 | Advanced Statistical Methods Courses |
CBHS 6620 | Survey Research |
ECON 5813 | Econometrics I (UCD downtown campus) |
ECON 5823 | Econometrics II (UCD downtown campus) |
EPID 6632 | Advanced Epidemiology |
EPID 6646 | Introduction to Systematic Reviews |
EPID 6635 | Epidemiology of Communicable Disease |
EPID 6636 | Chronic Disease Epidemiology |
EPID 6638 | Cardiovascular Epidemiology |
EPID 6639 | Genetic and Molecular Epidemiology |
HSMP 6603 | Health Care Systems |
HSMP 6609 | Cost Benefit and Effectiveness in Health |
HSMP 6617 | Introduction to Health Services Research |
HSMP 6625 | Methods in Health Services Research |
The program’s strengths in outcomes research are emphasized in 35 credits of several areas:
The program has experience in accessing a multitude of data such as MEPS, PHARMetrics, University Health-System, Consortium and MarketScan. Students are encouraged to utilize these datasets as well as primary data collection. Students may enroll in courses not listed (e.g courses in downtown campuses and/or newly developed courses) by consulting with the program director.
Pharmacoeconomics.
Pharmaceutical and drug related policy.
Antal Zemplényi
Antal Zemplényi, PhD, is an Associate Professor at the Center for Health Technology Assessment at the University of Pécs and a senior researcher at the Syreon Research Institute, an international research corporation specializing in health policy, health economic modeling, and technology assessment. He has experience in value assessment, HTA, health economics and outcomes research, and real-world data analysis. He is the past president of the ISPOR Hungary Chapter. Antal is currently a Fulbright Scholar at the University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences working as a visiting research associate in the Pharmaceutical Value (pValue) initiative.
Monica Bianchini is originally from Indianapolis, Indiana. She received a PharmD and MPH from the University of Wisconsin-Madison in 2017. She subsequently completed a hospital pharmacy residency (PGY-1) and Infectious Diseases PGY-2 at Henry Ford Hospital in Detroit, Michigan. Monica joined CePOR in 2019 and currently works as a clinical inpatient pharmacist. Her dissertation will evaluate opportunities to decrease syphilis rates and improve syphilis care in Colorado. Outside of work, she enjoys reading, live music, cooking, and anything outside (running, hiking, backpacking, skiing).
Sue is a fifth year PhD student at CePOR. Her dissertation focuses on characterizing the burden of MS and treatment strategies using real-world claims data. Prior to grad school, she studied Neuroscience in Pomona College. In her free time, Sue enjoys taking her puppies on adventures.
Mahesh Maiyani was born and raised in India. He earned his Bachelor of Pharmacy (BPharm) from India in 2006 and then he came to the US to pursue his Master’s in Business administration. He completed his MBA from The University of Findlay in Ohio. He has work experience in clinical trials and heath care research. He joined the Pharmaceutical Outcomes Research PhD program in Fall-2021. His research interests are focused around cost effectiveness in real-world clinical settings. Mahesh enjoys hiking and spending time with family and friends.
Nick Mendola was born and raised in Buffalo, New York. He graduated from The University of Akron with a BS in Exercise Science in 2016. He then moved to Washington D.C. to attend The George Washington University Milken Institute School of Public Health, where he obtained his MPH in Epidemiology, in 2018. During this time, he worked researching the impact of the pharmaceutical industry’s marketing to healthcare professionals, and its influence on prescribing practices and population level drug utilization. Nick joined the Pharmaceutical Outcomes Research program in the fall of 2018. Nick’s current work with Dr. Robert Brett McQueen, explores the use of Multi-Criteria Decision Analysis (MCDA) as a novel health technology value assessment tool. His work specifically explores MCDA in evaluating treatments for neuromyelitis optica spectrum disorder (NMOSD), a rare neurological disorder.
Vanessa Patterson is originally from Kansas City. She graduated from Tulane University School of Public Health and Tropical Medicine with an MPH concentrating in Epidemiology and Maternal and Child Health in 2012. Vanessa went on to work as an applied epidemiologist for government public health agencies for six years. She joined the Pharmaceutical Outcomes Research program at CU in the fall of 2018. Working under the mentorship of Dr. Heather Anderson, Vanessa is currently a PhRMA Foundation Predoctoral Fellow and a PhD candidate. Her dissertation focuses on the utilization of cardioprotective medications among women with a history of breast cancer. In her free time, Vanessa enjoys making pottery and spending time outdoors with family and friends.
Sammi is originally from Taiwan. She holds a bachelor’s degree in Pharmacy from Kaohsiung Medical University. After graduation, she had worked in pharmaceutical companies and clinical research organizations for several years before coming to the US. She completed her Master’s training at the University of Pittsburgh, Pharmaceutical Outcomes and Policy Research, in 2022. And then she joined Pharmaceutical Outcomes Research PhD program at CU Anschutz in Fall 2022. Her research interest lies in the intersection of pharmacoeconomics, real-world evidence, and pharmaceutical outcomes. Outside the schoolwork, she enjoys cooking, baking, and snowboarding/skiing in winter.
Mouna was born and raised in Tunisia. She graduated with a PharmD from the University of Pharmacy of Monastir in 2016. She then worked for two years at a consulting company focusing on pharmaceuticals’ Pricing, Reimbursement and Market Access (PRMA) in Europe. After that, she was awarded with the Fulbright Foreign student scholarship and moved to Colorado, where she obtained her MPH in Global Health Systems, management, and Policy in 2022. Mouna joined the Pharmaceutical Outcomes Research program in the fall of 2022. Her research interests include evaluating the use of Health Technology Assessment in the context of low- and middle- income countries and developing tools that permit equitable patients’ access to cost-effective technologies. In her free time, Mouna enjoys learning new languages, improv theatre and cooking.
“One key reason I chose to join CePOR at CU was the tight-knit group of faculty and students. Given the program is smaller, the faculty has a better opportunity to stay in touch with all the students and provide support for everyone's research, regardless if they're on the student's committee or not. The student group is also very close as we are together for weekly seminars and enjoy out-of-school gatherings when possible. Another draw of CU's POR program is the diverse expertise of our faculty and alumni. Our current faculty have a range of expertise including: pharmacoepidemiology using big data sources, pharmacoeconomics and drug pricing, rare diseases, opioid use disorder and treatment, and Medicare payment models. Recent alumni have found work in a variety of different fields from consulting to academia to the pharmaceutical industry and the public health department. The wide range of backgrounds and areas of expertise covered by our faculty and alumni provide so many resources for mentorship and future career planning. Finally, there are so many unique opportunities within CePOR to work with different data sources (e.g. electronic health records, national claims data, Medicaid claims data) and different methodology experts, so I am confident that our program could be a great fit for prospective PhD students of all backgrounds.” – Monica Bianchini, PharmD, MPH
“CU's Pharmaceutical Outcomes Research Program produces robust interdisciplinary research that spans from pharmacoepidemiology to pharmaceutical economics with a variety of collaborators, such as Institute for Clinical and Economic Review (ICER) and Colorado Department of Public Health & Environment (CDPHE).” – Sue Kwon, BA
“I joined the POR program because my previous research was focused on population drug utilization and the pharmaceutical industry’s impact on prescribing practices, and the POR program seemed like a natural fit for me to be able to keep learning about the areas of pharmacoepidemiology and drug related policy. What I like most about the program so far has been the core faculty in our program. They seem to truly care about student success and how we progress both academically and professionally. ” – Nick Mendola, MPH
Mission: To educate, increase awareness and promote growth within the 'Pharmacoeconomics and Outcomes Research' field in general and to increase the CU Denver presence among the international society ISPOR. To collaborate across different sciences on campus and different departments worldwide.
Description: Promote pharmacoeconomics and outcomes research education by holding regular seminars on current issues in the field and presenting research at least once a year at the annual meeting in the US-Canada region.
Membership requirements: We expect members to be passionate about the kind of research that is involved related to public health, epidemiology, pharmacoeconomics, and policy. Also, attending our regular educational seminars/webinars is highly encouraged.
Activities: Details will be emailed to members soon!
Benefits: The opportunity to present research, network and collaborate with faculty from different universities around the world, professionals from industry and research organizations at a global level.
Officers for 2020-2021 | |
President | |
Vice President |
Julia Slejko, PhD ('12) Associate Professor Practice, Sciences, and Health Outcomes Research University of Maryland School of Pharmacy
R. Brett McQueen, PhD ('13) Associate Professor Department of Clinical Pharmacy, Skaggs School of Pharmacy and Pharmaceutical Sciences University of Colorado Anschutz Medical Campus
William Padula, PhD ('13) Assistant Professor of Pharmaceutical and Health Economics, School of Pharmacy Fellow, Leonard D. Schaeffer Center for Health Policy & Economics University of Southern California
David Tabano, PhD ('18) Principal Health Economist Evidence for Access (E4A) | Public Affairs & Access Genentech, Inc.
Katie Sullivan, PhD ('18) Prescription Drug Epidemiologist Colorado Department of Public Health and Environment
Angela Czaja, MD, PhD ('19) Associate Professor Pediatrics-Critical Care Medicine Children’s Hospital Colorado Anschutz Medical Campus
Chong Kim, PhD ('20) Associate Director Global Value & Access | HEOR Gilead Sciences
Katia Hannah, PhD ('21) Lead HEOR Specialist Dexcom
Kimberly Deininger, PhD ('22) HEOR Manager Amgen
Isabella Jaramillo Email: [email protected] Phone: 303.724.7263
Assistant Professor; Director, Pharmaceutical Outcomes Research PhD Program Email: [email protected] Phone: 434-466-1990
CU Anschutz
Pharmacy and Pharmaceutical Sciences Building
12850 East Montview Boulevard
Aurora, CO 80045
303-724-2882
Back to Blog
If you’re investigating a pharmacy or pharmaceutical science career, choosing the right educational path can feel like deciphering a complex prescription. We’re here to help break down the key differences between three popular degrees: Doctor of Pharmacy (PharmD), Master of Science in Pharmaceutical Sciences (MS), and Doctor of Philosophy (PhD) in Pharmaceutical Sciences.
Note: Mercer University is one of the few colleges in the South offering all three degrees. Learn more about the programs we offer.
The Doctor of Pharmacy (PharmD) is a professional doctorate specifically designed to prepare you for a career as a licensed pharmacist. Pharmacists are the medication experts on the healthcare team, ensuring patients receive the right drugs at the correct dosage. PharmD grads work mostly in front-of-the-line careers in retail, hospital and other patient-forward settings. And yes, since this is a doctorate program, you can be called “Doctor” after graduation!
Interested? Contact our admissions department for more information and to get started .
A MS is a more research-oriented degree than the PharmD . It provides a strong foundation in the scientific principles underlying drug discovery, development, and delivery.
If you have more questions, don’t hesitate to get in touch with our admissions department for more information .
The Doctor of Philosophy (PhD) is the ultimate research degree , preparing you for a career at the forefront of scientific discovery in pharmaceuticals. It emphasizes independent research, culminating in a dissertation that significantly contributes to the field.
Get more details about our program and admissions requirements by contacting our admissions department .
The best degree for you depends on your career goals. Consider these factors:
No matter which path you choose, a degree in pharmaceutical sciences equips you to make a real difference in people’s lives. Whether it’s ensuring safe and effective medication use, developing new life-saving drugs, or advancing our understanding of diseases, your work will have a positive impact on the world.
Remember, this is just a starting point. Our admissions advisors are here to help and answer your questions. Also, talk to professionals in the field, and do more online research. With the right information and a clear vision, you can unlock a rewarding career in the exciting world of pharmacy!
*Duration of program is typical for full-time students.
URI’s College of Pharmacy is a diverse community of scholars who work together and inspire one another in our teaching, research, practice, and service. Our big idea is to improve the quality of life for people in our local, national, and global communities. We welcome you to join us at our beautiful campus near the ocean where you can do your very best work in brand new, cutting-edge facilities that give you the perfect resources to learn, grow, and put your ideas into practice.
Pharmaceutical sciences m.s., pharmaceutical sciences ph.d..
In late June, the Accreditation Council for Pharmacy Education announced the Thomas J. Long School of Pharmacy’s doctor of pharmacy (PharmD) program was granted a full 8-year accreditation. This notable accomplishment affirms the high caliber of Pacific’s student-centered PharmD program.
“This achievement reflects our commitment to excellence in pharmacy education,” said Dean Berit Gundersen ’84 , PharmD. “This is also a testament to the dedication and hard work of faculty, staff and students. Receiving a full 8-year accreditation underscores the quality of our academic program. I am incredibly proud of the collective efforts that led us to this outcome.”
“We will continue to strive for excellence, preparing our students to be leaders who are passionate about meeting the evolving health care needs of our communities.”
The accreditation, which extends through June 2032, allows the School to focus on preparing students for the future of the pharmacy profession.
“As we celebrate this achievement, we also look to the future with a sense of purpose,” Dean Gundersen said. “The accreditation validates our current practices and sets the stage for continuous improvement and innovation. We will continue to strive for excellence, preparing our students to be leaders who are passionate about meeting the evolving health care needs of our communities.”
The rigorous self-study was a collaborative endeavor and showcases the dedication of faculty, staff, students and alumni.
“A heartfelt thanks to all who contributed to this tremendous accomplishment,” Dean Gundersen said. “Your dedication, passion and hard work have made this possible.”
Dean Berit Gundersen ’84, PharmD and Srikanth Kolluru, MSPharm, PhD, associate dean for academic affairs, with doctor of pharmacy students
Subscribe to our newsletter , related news.
By Samantha Rzeszut
Published September 20, 2023
Robert Bies, PharmD, PhD, professor, Department of Pharmaceutical Sciences, has been appointed associate dean for Graduate Education, effective September 1.
In this newly established role, Bies will bring leadership to the PhD programming at the University at Buffalo (UB) School of Pharmacy and Pharmaceutical Sciences (SPPS). His primary responsibility will be growing our PhD programming and associated areas involving recruitment, budgeting and governance.
Bies will oversee all aspects of our on-site graduate programs and will advance the impact of our on-line MS programming. He will lead the division directors of Graduate Studies in managing our Pharmaceutical Sciences PhD and MS programs, the Pharmacometrics and Personalized Pharmacotherapy and the Clinical and Translational Therapeutics MS programs and will also lead the Office for Graduate Education.
“This is a very unique time at the School of Pharmacy and Pharmaceutical Sciences with significant growth and evolution of the graduate programs encompassing the PhD in Pharmaceutical Sciences and the MS degrees in Pharmaceutical Sciences, Pharmacometrics and Personalized Pharmacotherapy and Clinical and Translational Therapeutics,” says Bies.
Bies earned his PharmD from the University of Texas at Austin and University of Texas Health Science Center San Antonio in 1994 and his PhD Pharmacology degree from Georgetown University in 1998. He then went on to complete postdoctoral training at Georgetown University in the Center for Drug Development Sciences until 2000. From 2000-2009 he served as an assistant professor at the University of Pittsburgh School of Pharmacy. He went on to serve as associate professor of Medicine and Medical and Molecular Genetics at the Indiana University School of Medicine and as director of the Disease and Therapeutic Response Modeling program for the Indiana Clinical Translational Sciences Institute from 2009-2015.
In 2015 Bies joined SPPS and currently serves as a professor in the Department of Pharmaceutical Sciences. He is also a member of the UB Institute for Computational Data Science. Bies additionally serves as a project scientist at the Centre for Addiction and Mental Health, University of Toronto, is on the editorial boards for numerous scientific journals and is a member of several national scientific organizations.
His research focuses on the application of pharmacometric approaches in HIV, addiction, psychiatry, oncology, and neurology and novel methods development including machine learning approaches to model selection and optimization methods for parameter optimization in dynamic systems.
“I am delighted to have the opportunity to engage in this role,” Bies adds. “I look forward to working with my colleagues and the Dean to shepherd the graduate programs through this period of significant change.”
For over 135 years, the University at Buffalo School of Pharmacy and Pharmaceutical Sciences has continually been a leader in the education of pharmacists and pharmaceutical scientists, renowned for innovation in clinical practice and research. The school is accredited by the American Council of Pharmaceutical Education and is the No. 1 ranked school of pharmacy in New York State and No. 14 in the United States by U.S. News & World Report.
Send us a Text Message.Dr. William Padula, PhD, MS, MSc, is Assistant Professor, Pharmaceutical & Health Economics and Fellow, Schaeffer Center for Health Policy & Economics, at the Alfred E. Mann School of Pharmacy & Pharmaceutical Sciences, University of Southern California ( https://healthpolicy.usc.edu/author/william-padula-phd/ ). His research explores the theoretical foundations of medical cost-effectiveness analysis, especially pertaining to issues around the value of vacci...
The .gov means it’s official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
Checking a pharmacy’s license through your state board of pharmacy is an important step in knowing whether you are using a safe online pharmacy. Click on your state to look for your online pharmacy in the state’s board of pharmacy license database. If your online pharmacy is not listed, you should not use that pharmacy. If your pharmacy is listed, please also confirm that the pharmacy:
IMAGES
VIDEO
COMMENTS
Why Study Pharmacy in United States. Studying Pharmacy in United States is a great choice, as there are 45 universities that offer PhD degrees on our portal. Over 957,000 international students choose United States for their studies, which suggests you'll enjoy a vibrant and culturally diverse learning experience and make friends from all ...
The PhD in Pharmaceutical Sciences (PSC) program is a highly competitive doctoral degree program within the University of Maryland School of Pharmacy. Curricular Requirements How to Apply PSC Faculty Sign-Up for Updates. NIH Initiative for Maximizing Student Development (IMSD) Learn about our program that supports biomedical graduate students ...
1,989,687,500 EUR / year. 4 years. The School of Pharmacy and Pharmaceutical Sciences (SOPPS) at Binghamton University offers a graduate-level pharmacy program culminating in the professional degree of Doctor of Pharmacy (PharmD). Ph. D. / Full-time / On Campus. Binghamton University Binghamton, New York, United States.
The PhD program in pharmaceutical sciences includes coursework as well as cutting-edge research focused on topics like discovery and evaluation of novel drugs, determination of a drug's effects on the body, delivery methods to improve drug treatment, and how medication is used and applied to enhance patient outcomes. Because the scope of ...
Pharmaceutical Sciences participates in the joint PharmD/PhD program, which trains students for careers in academic pharmacy and bench science research. Students admitted to this joint program participate in the PharmD curriculum and pursue original doctoral research projects in the laboratories of the university's graduate faculty in the ...
Doctor of Philosophy (PhD) The UB Department of Pharmaceutical Sciences is the foremost destination for PhD student scholars interested in challenging the boundaries of drug discovery, development and evaluation. We invite you to study with our group of internationally renowned faculty as they advance the biotherapies and technologies of the ...
PhD and MS Programs in Pharmaceutics. PhD Application deadline: applications must be submitted by December 15th, 2024 for admission to begin the program in Autumn Quarter 2025. MS Application deadline: Applications are accepted for Autumn admission only. Applications must be submitted by January 15th, 2025 for admission to begin the program in ...
The College of Pharmacy has established a maximum limit of 8 years for completion of any graduate program, although some programs in the College may have established shorter time limits for completion of certain degrees. These research-based degrees typically qualify graduates for work in the following research-related areas: performing research.
Pharmaceutical Sciences PhD. The PhD in Pharmaceutical Sciences at Temple University's School of Pharmacy is a rigorous, research-based graduate course of study that prepares you for advanced scientific research. The curriculum integrates biochemistry, organic chemistry, pharmaceutics and pharmacology. You will acquire expertise on drug synthesis, action, delivery and disposition.
University of Houston College of Pharmacy's Doctorate of Pharmacy (Pharm.D.) program is a four-year professional program that prepares individuals for a variety of areas within the pharmacy profession. Doctorate / Full-time / On Campus. University of Houston Houston, Texas, United States. Ranked top 4%.
First year pharmacy students can pursue the PharmD/PhD degree by conducting 3 research rotations with faculty on research topics of PSDD during years 1-2 of the pharmacy curriculum. Pharmacy students in their 2nd year can apply for admissions for the PhD program of the Biomedical Sciences graduate program at UCSD (see previous paragraph).
Fall 2025 Admission Deadline: December 2, 2024 PhD in Pharmacological Sciences UC Irvine's PhD in Pharmacological Sciences program provides a unique opportunity for those interested in any scientific discipline represented by the Pharmaceutical Sciences faculty to have a year of broad, interdisciplinary training and self-selected lab rotations followed by focused doctoral research in the ...
Contact us at: [email protected]. The Pharmaceutical Sciences PhD Program at the University of Wisconsin-Madison provides a rigorous background in scientific disciplines that are critical to the preparation of the next generation of pharmaceutical scientists. With approximately 30 faculty trainers and approximately 65 graduate ...
MS and Ph.D. degrees are available in Pharmaceutics, Medicinal Chemistry, Pharmacology and Toxicology. Details on specific areas of research emphasis can be found on our faculty research page. Scientists from major pharmaceutical companies in the region provide support to our graduate programs through collaborative research engagement and ...
The degree was earned from a country where the official language is English (e.g., United States of America, Australia, England). ... The College of Pharmacy admits new graduate students for the fall term only. The deadline for each PhD program is: Medicinal Chemistry: December 1; Pharmaceutical Sciences: December 1; Clinical Pharmacy ...
PhD Program. The Pharmaceutical & Translational Sciences (PHTS) Program brings together, under one umbrella, the school's three laboratory-based PhD programs—CXPT, MPTX, PSCI. This promotes a more cohesive interdisciplinary experience advancing education and offering opportunities to sample the entire range of innovative research options.
The PHSC program will prepare students for executive positions in academia, research, education, government, industry, and related fields. These new leaders of pharmacutical sciences will identify, research, and problem-solve issues related to pharmaceutical sciences. The proposed PhD program will provide education and research training for a ...
Doctor of Philosophy (PhD) The UB Department of Pharmaceutical Sciences is the foremost destination for PhD student scholars interested in challenging the boundaries of drug discovery, development and evaluation. We invite you to study with our group of internationally renowned faculty as they advance the biotherapies and technologies of the ...
The graduate program in Pharmaceutical Sciences spans the entire life cycle of a drug, from bench to bedside. The Medicinal Chemistry concentration focuses on drug discovery and development, part of the pre-clinical studies phase of the cycle. Pharmaceutical Sciences Ph.D. Programs Distinction through five interrelated training opportunities involving the entire life cycle of a drug.…
SA.556 (The United States) SA.620 (Global Policy) SA.630/ 635 (Global Risk) SA.670 (Strategy, Cybersecurity and Intelligence) SA.685 (Sustainable Energy - Online) ... The Department of Pharmacology and Molecular Sciences hosts the Pharmacology Graduate Program, which offers a program of study and research leading to the Ph.D. degree. ...
The Weill Cornell Pharmacology Graduate Program was rated 4th in the USA in New York City by the prestigious National Research Council. The National Research Council (NRC) of the USA is the working arm of the National Academies of the United States. To find out more about the Weill Cornell Pharmacology PhD Program, view our rating. This rating ...
Pharmaceutical Outcomes Research is a PhD program in the graduate program in Clinical Pharmacy. This program is housed in the Center for Pharmaceutical Outcomes Research (CePOR, SEE-por), a school-wide center in the Skaggs School of Pharmacy. Our doctoral curriculum is designed to provide competent and highly skilled researchers in the study of ...
Our graduate programs are research-focused that immerse students in diverse aspects of drug action, from drug discovery to various elements of drug evaluation. ... Program Contact. Jennifer Rosenberg 274 Pharmacy Building Buffalo, NY 14214 Email: [email protected] Phone: 716-645-2825. Learn more about the program. Instruction Method . In ...
Note: By enrolling in the spring semester, our students can graduate in just three years.* Career options: Community pharmacy, hospital pharmacy, specialty pharmacy, clinical research, and medication therapy management. Requirements: Mercer requires several undergraduate pre-requisite courses to apply. While many of our students have bachelor ...
URI's College of Pharmacy is a diverse community of scholars who work together and inspire one another in our teaching, research, practice, and service. Our big idea is to improve the quality of life for people in our local, national, and global communities. We welcome you to join us at our beautiful campus near the […]
In late June, the Accreditation Council for Pharmacy Education announced the Thomas J. Long School of Pharmacy's doctor of pharmacy (PharmD) program was granted a full 8-year accreditation. This notable accomplishment affirms the high caliber of Pacific's student-centered PharmD program.
Robert Bies, PharmD, PhD, professor, Department of Pharmaceutical Sciences, has been appointed associate dean for Graduate Education, effective September 1. ... "This is a very unique time at the School of Pharmacy and Pharmaceutical Sciences with significant growth and evolution of the graduate programs encompassing the PhD in Pharmaceutical ...
Send us a Text Message.Dr. William Padula, PhD, MS, MSc, is Assistant Professor, Pharmaceutical & Health Economics and Fellow, Schaeffer Center for Health Policy & Economics, at the Alfred E. Mann School of Pharmacy & Pharmaceutical Sciences, University of Southern California ( https://healthpolicy.…
Checking a pharmacy's license through your state board of pharmacy is an important step in knowing whether you are using a ... Provides a physical address and telephone number in the United States;